Grail GRAL
NASDAQ GRAL
$80.77 +0.82 (+1.03%)
At close: Sep 18, 2026 · 4:00 PM EDT

Grail (GRAL) Cash from Financing Activities (2023 - 2025)

Grail's (GRAL) quarterly Cash from Financing Activities came in at $423.3 million in Q4 2025, down 54.59% quarter-over-quarter from $932.3 million in Q2 2024.

Analysis

Grail (GRAL) Cash from Financing Activities (2023 - 2025) Analysis & Trends

Grail (GRAL) has reported Cash from Financing Activities for 3 consecutive years, with $423.3 million the latest figure, recorded in Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities changed N/A year-over-year to $423.3 million; the trailing twelve-month figure through Dec 2025 stood at $423.3 million (down 65.98% YoY), and the FY2025 full-year result was $423.3 million, down 65.98% from the prior year.
  • Cash from Financing Activities eased to $423.3 million in Q4 2025 per GRAL's latest filing, from $932.3 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $932.3 million in Q2 2024 and bottomed at $74.0 million in Q4 2023.
  • Historically, Cash from Financing Activities has averaged $365.5 million across 3 years, with a median of $312.0 million in 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Natera 53.05 Bn 51.95 Bn 486.15 Mn 12.21 Mn
2 Quest Diagnostics 27.19 Bn 26.87 Bn 1.03 Bn -229.00 Mn
3 Labcorp Holdings 25.93 Bn 25.81 Bn 1.11 Bn -919.90 Mn
4 Guardant Health 23.97 Bn 22.91 Bn 219.03 Mn 23.01 Mn
5 Tempus AI 13.64 Bn 12.82 Bn 274.25 Mn 97.12 Mn
6 Caris Life Sciences 8.47 Bn 7.68 Bn 182.38 Mn -36.90 Mn
7 Sotera Health 5.35 Bn 4.99 Bn 177.96 Mn -2.41 Mn
8 BillionToOne 4.96 Bn 4.41 Bn 77.11 Mn 6.09 Mn
9 Adaptive Biotechnologies 4.55 Bn 4.21 Bn 51.39 Mn 142.19 Mn
10 Grail 3.61 Bn 2.75 Bn 21.34 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 423.32 Mn
Jun 30, 2024 932.30 Mn
Mar 31, 2024 312.00 Mn
Dec 31, 2023 85.99 Mn
Oct 1, 2023 74.01 Mn